Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$8.29 USD

8.29
27,781,652

-0.70 (-7.79%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $8.28 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

by Zacks Equity Research

Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +13.79% and -4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +50.00% and -0.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -20.37% and +69.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IOVA Stock Drops 6% on $350M Common Stock Offering

by Zacks Equity Research

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.

Zacks Equity Research

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

by Zacks Equity Research

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?